drugset / Trial / NCT00873756
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label study enrolling a total of up to 23 patients.
Timeline
- Start
- 2009-05
- Primary completion
- 2014-03
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dulanermin | Protein / enzyme biologic | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |